Clinical Registry & Platform
Recent Clinical Updates
Loading latest clinical updates

Clinical Intelligence & Drug Records for US-Licensed Practitioners

The integrated, institutional-grade registry trusted by US-licensed practitioners for evidence-based clinical data, drug information, and peer-reviewed clinical updates.

Clinical Update Briefing

Weekly drug approvals, safety updates, and specialty coverage for healthcare professionals.

Clinical Resources

Drug updates, reference data, and specialist-led coverage.

Recent Clinical Updates

Latest Drug & Specialty Updates

View All

Specialty Coverage

Therapeutic-area updates for clinical review.

All Specialties

Drug Information

FDA drug records and prescribing context.

Review drug records, NDC references, dosage tools, and interaction resources alongside clinical coverage.

Clinical Coverage

Additional Clinical Updates

Oncology

FDA Approves durvalumab for BCG‑naïve NMIBC: DFS HR 0.68 in POTOMAC

5h ago|5 min read|By Dr. Rahul Verma
Infectious Disease

Ciprofloxacin Guidance for Salmonella Infections and Resistance Considerations

5h ago|6 min read|By Dr. Simran Kohli
Oncology

FDA Approves Capivasertib for HR+ HER2− Breast Cancer: Cuts Progression Risk 50% in CAPItello-291

5h ago|7 min read|By Dr. Meera Pillai
Endocrinology

FDA Approves Tirzepatide (Zepbound) for Chronic Weight Management: 18% Mean Weight Loss in Trial

5h ago|8 min read|By Dr. Amit Desai
Oncology

FDA Approves Tregzi for Matched-Donor HSCT: 78% vs 38.4% cGFS

Sep 5|6 min read|By Dr. Meera Pillai
Oncology

FDA Approves Palbociclib (Ibrance) for HR+ HER2+ Metastatic Breast Cancer: Cuts Progression Risk 25% (HR 0.75)

Sep 5|5 min read|By Dr. Rahul Verma
Oncology

FDA Approves vepdegestrant for ESR1‑mutant ER+ Breast Cancer: PFS HR 0.57

Sep 4|6 min read|By Dr. Rahul Verma
Rheumatology

Golimumab Immgolis Approved as Interchangeable for RA and UC

Sep 4|6 min read|By Dr. Deepak Nair
Dermatology

FDA Approves roflumilast (ZORYVE) for Plaque Psoriasis: 71.9% Intertriginous‑IGA Success at Week 8

Sep 3|5 min read|By Dr. Divya Agarwal
Rheumatology

FDA Approves Deucravacitinib for Active Psoriatic Arthritis

Sep 3|5 min read|By Dr. Deepak Nair
Cardiology

FDA Approves Olezarsen for FCS: Cuts TG 43% vs Placebo

Sep 3|7 min read|By Dr. Kavya Sharma
Nephrology

FDA Approves Sparsentan for FSGS Without Nephrotic Syndrome: 29% Proteinuria Reduction in DUPLEX Non‑Nephrotic Subgroup

Sep 3|5 min read|By Dr. Praveen Singh
Pulmonology

Smoking Cessation: FDA-Recognized NRT, Varenicline, and Bupropion Options

Sep 3|5 min read|By Dr. Nikhil Chatterjee
Pharmacology

FDA Approves Ensitrelvir (XOCOVA) for COVID-19 Post-Exposure: 67% Lower Symptomatic Infection in SCORPIO-PEP

Sep 2|5 min read|By Dr. Pooja Sinha
Oncology

FDA Approves Datopotamab Deruxtecan for Unresectable TNBC: 36% ORR

Sep 2|5 min read|By Dr. Meera Pillai
Ophthalmology

FDA Approves Veligrotug for Thyroid Eye Disease: 70% PRR in THRIVE

Sep 2|6 min read|By Dr. Ravi Krishnan
Rare Disease

Lunsotogene parvec (Otarmeni) FDA Approves for OTOF-Associated Hearing Loss: 80% Hearing Response

Sep 2|5 min read|By Dr. Lakshmi Venkatesan
Gastroenterology

FDA Approves bulevirtide for chronic HDV: 48% combined response at Week 48

Sep 1|5 min read|By Dr. Sanjay Iyer
Dermatology

FDA Approves Roflumilast (ZORYVE) Cream for Plaque Psoriasis: IGA Success 41.5% (DERMIS-1)

Sep 1|5 min read|By Dr. Rohan Gupta
Rheumatoid Arthritis

NORD-STAR: Abatacept Achieved 59.3% CDAI Remission in Early RA

Aug 31|7 min read|By Dr. Deepak Nair
Pulmonology

Trimbow, Trelegy, Breztri: triple-inhaler dosing and label differences for asthma

Aug 30|6 min read|By Dr. Nikhil Chatterjee
Pulmonology

FDA Approves Trimbow for Asthma: Trough FEV1 Gains 57–73 mL

Aug 29|5 min read|By Dr. Nikhil Chatterjee
Pulmonology

FDA Approves Trimbow for Maintenance Treatment of Asthma

Aug 29|5 min read|By Dr. Nikhil Chatterjee